Table 3.
Characteristics | Cases* | Controls* | Odds Ratio | 95% Confidence Interval | ||
---|---|---|---|---|---|---|
N | % | N | % | |||
Never/rare | 1,188 | 50 | 12,714 | 53 | 1.00 | |
Shorter-term <10 years: | ||||||
Low Intensity† | 317 | 13 | 2,997 | 13 | 1.09 | 0.96 to 1.25 |
Medium Intensity‡ | 210 | 9 | 2,078 | 9 | 1.03 | 0.88 to 1.20 |
High Intensity+ | 332 | 14 | 2,961 | 12 | 1.16 | 1.01 to 1.33 |
Long-term 10 to </= 15 years: | ||||||
Low Intensity† | 151 | 6 | 1,301 | 5 | 1.18 | 0.98 to 1.42 |
Medium Intensity‡ | 81 | 3 | 773 | 3 | 1.06 | 0.83 to 1.35 |
High Intensity+ | 88 | 4 | 971 | 4 | 0.90 | 0.71 to 1.13 |
Long-term >15 years: | ||||||
Low Intensity† | 6 | 0.3 | 76 | 0.3 | 0.80 | 0.35 to 1.85 |
Medium Intensity‡ | 16 | 0.7 | 74 | 0.3 | 2.30 | 1.30 to 4.06 |
High Intensity+ | 10 | 0.4 | 96 | 0.4 | 1.01 | 0.52 to 1.97 |
¤(sCox-2 inhibitors, aspirin, and non-aspirin non-selective NSAID). * Matched on county of residence and birth year. ^Analyses adjusted for use of hormone replacement therapy, history of rheumatoid arthritis and migraine. † Low intensity was prescription use <25% of duration. ‡ Medium intensity was prescription use >25% but <50% of duration. + High intensity was prescription use >50% of duration.